<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39371208</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Predicting herd immunity achievement: a time-series analysis of vaccination and fatality rates using 1,075 days of COVID-19 data.</ArticleTitle><Pagination><StartPage>1403163</StartPage><MedlinePgn>1403163</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1403163</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1403163</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The COVID-19 pandemic, driven by SARS-CoV-2, has made vaccination a critical strategy for global control. However, vaccine hesitancy, particularly among certain age groups, remains a significant barrier to achieving herd immunity.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study uses Poisson regression and ARIMA time-series modeling to identify factors contributing to vaccine hesitancy, understand age-specific vaccination preferences, and assess the impact of bivalent vaccines on reducing hesitancy and fatality rates. It also predicts the time required to achieve herd immunity by analyzing factors such as vaccine dosing intervals, age-specific preferences, and changes in fatality rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The study finds that individuals recovering from COVID-19 often delay vaccination due to perceived immunity. There is a preference for combining BNT162b2 and CoronaVac vaccines. The BNT162b2 bivalent vaccine has significantly reduced vaccine hesitancy and is linked with lower fatality rates, particularly in those aged 80 and above. However, it tends to induce more severe side effects compared to Sinovac. Vaccine hesitancy is most prevalent among the youngest (0-11) and oldest (80+) age groups, posing a challenge to reaching 90% vaccination coverage.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Vaccine hesitancy is a major obstacle to herd immunity. Effective strategies include creating urgency, offering incentives, and prioritizing vulnerable age groups. Despite these challenges, the government should have continued to encourage vaccinations while gradually lifting COVID-19 control measures, balancing public health safety with the return to normal life, as was observed in the transition period during the latter stages of the pandemic.</AbstractText><CopyrightInformation>Copyright © 2024 Hon, Chan, Ng and Lam.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hon</LastName><ForeName>Benny Yiu Chung</ForeName><Initials>BYC</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Faculty of Science, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, School of Humanities and Social Sciences, University of Science and Technology of China, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chan</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>King George V School, Ho Man Tin, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Kei Shing</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Simon Ching</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>School of Nursing, Tung Wah College, Ho Man Tin, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032521" MajorTopicYN="Y">Immunity, Herd</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088823" MajorTopicYN="N">Vaccination Hesitancy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CoronaVac</Keyword><Keyword MajorTopicYN="N">herd immunity</Keyword><Keyword MajorTopicYN="N">time series analysis</Keyword><Keyword MajorTopicYN="N">vaccine hesitancy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371208</ArticleId><ArticleId IdType="pmc">PMC11449892</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1403163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prather KA, Marr LC, Schooley RT, McDiarmid MA, Wilson ME, Milton DK, et al. . Airborne transmission of SARS-CoV-2. Science. (2020) 370:303–4. doi: 10.1126/science.abf0521</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf0521</ArticleId><ArticleId IdType="pubmed">33020250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. . Coronavirus pandemic (COVID-19). Our World in Data. (2020). Available at: https://ourworldindata.org/coronavirus (Accessed March 18, 2024).</Citation></Reference><Reference><Citation>Yu BY-M, Lam JC-S, Lam SC, Li Y, Chen S, Lam MY, et al. . COVID-19 vaccine hesitancy and resistance in an urban Chinese population of Hong Kong: a cross-sectional study. Hum Vaccin Immunother. (2022) 18:2072144. doi: 10.1080/21645515.2022.2072144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2072144</ArticleId><ArticleId IdType="pmc">PMC9359377</ArticleId><ArticleId IdType="pubmed">35612813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok KO, Lai F, Wei WI, Wong SYS, Tang JW. Herd immunity–estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. (2020) 80:e32–3. doi: 10.1016/j.jinf.2020.03.027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.027</ArticleId><ArticleId IdType="pmc">PMC7151357</ArticleId><ArticleId IdType="pubmed">32209383</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J, Ng KS, Hon BYC, Lam SC. Suggestions to minimise hesitancy and promote vaccination of children in Hong Kong. Hong Kong Med J. (2023) 29:86. doi: 10.12809/hkmj2210487</Citation><ArticleIdList><ArticleId IdType="doi">10.12809/hkmj2210487</ArticleId><ArticleId IdType="pubmed">36603857</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana K, Mondal S, Nemade B. A review: data pre-processing and data augmentation techniques. Global Trans Proc. (2022) 3:91–9. doi: 10.1016/j.gltp.2022.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gltp.2022.04.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan R. How Hong Kong’s vaccination missteps led to the world’s highest covid-19 death rate. BMJ. (2022) 377:o1127. doi: 10.1136/bmj.o1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1127</ArticleId><ArticleId IdType="pubmed">35534035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PKS, Wong MCS, Wong ELY. Vaccine hesitancy and COVID-19 vaccination in Hong Kong. Hong Kong Acad Med. (2021) 27:90–1. doi: 10.12809/hkmj215115</Citation><ArticleIdList><ArticleId IdType="doi">10.12809/hkmj215115</ArticleId><ArticleId IdType="pubmed">33879624</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DJ, Hakim AJ, Leung GM, Xu W, Schluter WW, Novak RT, et al. . COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022. MMWR Morb Mortal Wkly Rep. (2022) 71:545–8. doi: 10.15585/mmwr.mm7115e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7115e1</ArticleId><ArticleId IdType="pmc">PMC9020860</ArticleId><ArticleId IdType="pubmed">35421076</ArticleId></ArticleIdList></Reference><Reference><Citation>Protection CfH . Seasonal influenza vaccination 2022/23: CHP, Department of Health, the government of the Hong Kong special administrative region; (2022). Available at:
https://www.chp.gov.hk/en/healthtopics/content/24/102466.html</Citation></Reference><Reference><Citation>Vardhanabhuti V, Ng KS. Differential impact of COVID-19 on Cancer diagnostic services based on body regions: a public facility-based study in Hong Kong. Int J Radiat Oncol Biol Phys. (2021) 111:331–6. doi: 10.1016/j.ijrobp.2021.05.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8448987</ArticleId><ArticleId IdType="pubmed">34004229</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh ML. The chi-square test of independence. Biochem Med. (2013) 23:143–9. doi: 10.11613/BM.2013.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.11613/BM.2013.018</ArticleId><ArticleId IdType="pmc">PMC3900058</ArticleId><ArticleId IdType="pubmed">23894860</ArticleId></ArticleIdList></Reference><Reference><Citation>Vig V, Kaur A. Time series forecasting and mathematical modeling of COVID-19 pandemic in India: a developing country struggling to cope up. Int J Syst Assur Eng Manag (2022);13:2920–3310.1007/s13198-022-01762-7.</Citation></Reference><Reference><Citation>Cheung E, Leung K. Hong Kong fourth wave: full delivery of city’s free coronavirus vaccine scheme ‘may take until end of 2021’ South China morning post. Sect Health Environ. (2020)</Citation></Reference><Reference><Citation>Mahase E. Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds. BMJ. (2021) 374. doi: 10.1136/bmj.n1875</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1875</ArticleId><ArticleId IdType="pubmed">34301631</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce MC, Mountjoy NJ, Johnson JA, Newman JT, Bandy DL, Atalla NA, et al. . From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community. BMC Public Health. (2022) 22:2351. doi: 10.1186/s12889-022-14824-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14824-z</ArticleId><ArticleId IdType="pmc">PMC9750730</ArticleId><ArticleId IdType="pubmed">36517842</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH . The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: what you need to know: World Health Organization; (2022) Available at:
https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know</Citation></Reference><Reference><Citation>Protection CfH . COVID-19 situation report - December 2022. CHP. Hong Kong: Department of Health, the government of the Hong Kong special administrative region; (2022).</Citation></Reference><Reference><Citation>Protection CfH . Scientific committees under CHP issue consensus interim recommendations on COVID-19 vaccination: the government of the Hong Kong special administrative region; (2021). Available at:
https://www.info.gov.hk/gia/general/202109/15/P2021091501003.htm</Citation></Reference><Reference><Citation>Plans-Rubió P. Percentages of vaccination coverage required to establish herd immunity against SARS-CoV-2. Vaccine. (2022) 10:736. doi: 10.3390/vaccines10050736</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050736</ArticleId><ArticleId IdType="pmc">PMC9144560</ArticleId><ArticleId IdType="pubmed">35632492</ArticleId></ArticleIdList></Reference><Reference><Citation>AAMC . Had COVID recently? Here’s what to know about how long immunity lasts, long COVID, and more: AAMC; (2022). Available at:
https://www.aamc.org/news/had-covid-recently-here-s-what-know-about-how-long-immunity-lasts-long-covid-and-more</Citation></Reference><Reference><Citation>Control CfD, Prevention . Frequently asked questions about COVID-19 Vaccination; (2023). Available at:
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html</Citation></Reference><Reference><Citation>Health NIo . Lasting immunity found after recovery from COVID-19; (2021) Available at:
https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19</Citation></Reference><Reference><Citation>Gellert P, Bethke N, Seybold J. School-based educational and on-site vaccination intervention among adolescents: study protocol of a cluster randomised controlled trial. BMJ Open. (2019) 9:e025113. doi: 10.1136/bmjopen-2018-025113, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-025113</ArticleId><ArticleId IdType="pmc">PMC6357342</ArticleId><ArticleId IdType="pubmed">30700487</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JD, Ackerman MS, Laspra B, Polino C, Huffaker JS. Public attitude toward Covid-19 vaccination: the influence of education, partisanship, biological literacy, and coronavirus understanding. FASEB J. (2022) 36:e22382. doi: 10.1096/fj.202200730, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202200730</ArticleId><ArticleId IdType="pmc">PMC9328288</ArticleId><ArticleId IdType="pubmed">35657606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertwee E, Simas C, Larson HJ. An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy. Nat Med. (2022) 28:456–9. doi: 10.1038/s41591-022-01728-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01728-z</ArticleId><ArticleId IdType="pubmed">35273403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WH-S, So H-K, Rosa Duque JS, Tso WW-Y, Chong PC-Y, Kwan MY-W, et al. . Impact of a focus education in zoom on COVID-19 vaccine hesitancy in Hong Kong parents of the preschoolers. Hum Vaccin Immunother. (2022) 18:208146010. doi: 10.1080/21645515.2022.2081460</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2081460</ArticleId><ArticleId IdType="pmc">PMC9621011</ArticleId><ArticleId IdType="pubmed">35671466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford HE, Elliman DAC. Fifteen-minute consultation: vaccine-hesitant parents. Arch Dis Child Educ Pract Ed. (2020) 105:194–9. doi: 10.1136/archdischild-2019-316927</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2019-316927</ArticleId><ArticleId IdType="pubmed">31575602</ArticleId></ArticleIdList></Reference><Reference><Citation>Akther T, Nur T. A model of factors influencing COVID-19 vaccine acceptance: a synthesis of the theory of reasoned action, conspiracy theory belief, awareness, perceived usefulness, and perceived ease of use. PLoS One. (2022) 17:e0261869. doi: 10.1371/journal.pone.0261869, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261869</ArticleId><ArticleId IdType="pmc">PMC8754289</ArticleId><ArticleId IdType="pubmed">35020764</ArticleId></ArticleIdList></Reference><Reference><Citation>Albano L, Ferrara P. Could fractional mRNA COVID-19 vaccines reduce myocarditis in adolescents? Travel Med Infect Dis. (2021) 44:102164. doi: 10.1016/j.tmaid.2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021</ArticleId><ArticleId IdType="pmc">PMC8437827</ArticleId><ArticleId IdType="pubmed">34534685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannus P, Depickère S, Kemlin D, Houben S, Neven KY, Heyndrickx L, et al. . Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS Glob. Public Health. (2022) 2:e0001308. doi: 10.1371/journal.pgph.0001308</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0001308</ArticleId><ArticleId IdType="pmc">PMC10021431</ArticleId><ArticleId IdType="pubmed">36962838</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozen GVT, Roukens AHE, Roestenberg M. COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness. Lancet Glob Health. (2022) 10:e570–3. doi: 10.1016/S2214-109X(22)00075-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00075-4</ArticleId><ArticleId IdType="pmc">PMC8923677</ArticleId><ArticleId IdType="pubmed">35303466</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal vaccination: a potential tool in the Battle against the COVID-19 pandemic? Risk Manag Healthc Policy. (2021) 14:2079–87. doi: 10.2147/rmhp.S309707</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/rmhp.S309707</ArticleId><ArticleId IdType="pmc">PMC8144901</ArticleId><ArticleId IdType="pubmed">34045909</ArticleId></ArticleIdList></Reference><Reference><Citation>Omer SB, Malani PN. Booster vaccination to prevent COVID-19 in the era of omicron: an effective part of a layered public health approach. JAMA. (2022) 327:628–9. doi: 10.1001/jama.2022.0892</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0892</ArticleId><ArticleId IdType="pubmed">35061011</ArticleId></ArticleIdList></Reference><Reference><Citation>Box GE, Jenkins GM, Reinsel GC, Ljung GM. Time series analysis: Forecasting and control. Hoboken, New Jersey: John Wiley &amp; Sons; (2015).</Citation></Reference><Reference><Citation>Schwarz G. Estimating the dimension of a model. Ann Stat. (1978) 6:461–4. doi: 10.1214/aos/1176344136</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aos/1176344136</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, Quach THT, Tran TM, Phuoc HN, Nguyen HT, Vo TK, et al. . Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomed Pharmacother. (2022) 147:112650. doi: 10.1016/j.biopha.2022.112650</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.112650</ArticleId><ArticleId IdType="pmc">PMC8767802</ArticleId><ArticleId IdType="pubmed">35066301</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Mix-and-match COVID vaccines ace the effectiveness test. Nature. (2021). doi: 10.1038/d41586-021-02853-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-02853-4.</ArticleId><ArticleId IdType="pubmed">34675430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aygün D, Önal P, Apaydın G, Çokuğraş H. Coronavirus infections in childhood and vaccine studies. Turk Arch Pediatr. (2021) 56:10–4. doi: 10.5152/TurkArchPediatr.2020.20255, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/TurkArchPediatr.2020.20255</ArticleId><ArticleId IdType="pmc">PMC8114597</ArticleId><ArticleId IdType="pubmed">34013223</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkmen D, Altunisik N. Commentary on ‘psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine’. J Eur Acad Dermatol Venereol. (2022) 36:e606. doi: 10.1111/jdv.18117</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18117</ArticleId><ArticleId IdType="pmc">PMC9114891</ArticleId><ArticleId IdType="pubmed">35352400</ArticleId></ArticleIdList></Reference><Reference><Citation>Protection CfH . Co-administration of COVID-19 vaccine and seasonal influenza vaccine: the government of the Hong Kong special administrative region; (2024). Available at:
https://www.chp.gov.hk/en/features/106096.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>